Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2023 | Long-term validity of amyloid-PET in a memory clinic population

Lyduine Collij, PhD, BioFINDER group, Lund University, Lund, Sweden, comments on her study assessing clinical outcomes up to 9 years after amyloid-PET in a symptomatic memory clinic population. Mortality rate was comparable in the amyloid-positive and amyloid-negative groups, but clinical decline was faster in the amyloid-positive cohort, reflected by MMSE, episodic memory, and fluency scores. Clinical etiological diagnosis was consistent with baseline in most patients, with no amyloid-negative patients receiving an Alzheimer’s disease diagnosis during follow-up. In all cases with neuropathological data available, amyloid-PET ruling was in line with post-mortem findings. These data support the validity of amyloid-PET. This interview took place at the CTAD 2023 conference in Boston, MA.

For more on the AMYPAD consortium:

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Dr. Collij has received research support from GE Healthcare and Springer Healthcare (paid by Eli Lilly). Both are paid to instituation. Dr. Collij’s salary is supported by the MSCA Doctoral Fellowship grant (#101108819) and Alzheimer Association Research Fellowship grant (#23AARF-1029663).